
    
      The aim of the current study to assess the efficacy of voclosporin in achieving complete or
      partial remission of proteinuria after 24 weeks of therapy in subjects with focal segmental
      glomerulosclerosis (FSGS). As well as to assess the safety and tolerability of voclosporin
      over 24 weeks in subjects with FSGS.
    
  